We observed elevated serum levels of C5b-9 (a marker of terminal complement pathway activation) in two patients in the aHUS subgroup, and elevated serum levels of Bb fragment of complement factor B (a marker of alternative complement pathway activation) in two patients in the aHUS subgroup, which is consistent with the proposed complement activation in COVID-19. The gene discussed is CFB; the disease is COVID-19.